Haemonetics
HAE

Haemonetics (HAE) news

Recent news

Haemonetics Corp: Barrington Research raises target price to $140 from $118

Barrington Research has revised its price target for Haemonetics Corp, raising it to $140 from $118, reflecting a positive reassessment of the company’s outlook. The adjustment indicates increased confidence in Haemonetics’ financial performance and strategic direction. Investors are advised to…

AInvest Wire · 3d ago

Haemonetics Corp: Mizuho raises target price to $140 from $95

AInvest Wire · 3d ago

Haemonetics shares jump 12.5% after supply agreement with CSL Plasma

Haemonetics Corp (NYSE:HAE) shares rose 16.01% to $104.72 as of Tuesday afternoon, reaching a new 52-week high, following the announcement of a supply agreement with CSL . The agreement allows CSL Plasma to use Haemonetics’ NexSys PCS devices with Persona PLUS technology across its U.S. collection…

AInvest Wire · 4d ago

Haemonetics Corp: BTIG raises target price to $130 from $110

BTIG, a financial services firm, has raised its price target for Haemonetics Corporation (HAE) to $130 per share from $110, reflecting a positive outlook on the company’s performance and potential growth. The updated target indicates increased confidence in Haemonetics’ business trajectory, though…

AInvest Wire · 4d ago

Csl - To complete Haemonetics platform rollout in U.S. plasma centres by end 2027

Haemonetics Corporation has announced plans to complete the rollout of its integrated platform across U.S. plasma centers by the end of 2027, as part of its broader strategy to enhance operational efficiency and market competitiveness. The company’s recent first-quarter fiscal 2027 earnings call…

AInvest Wire · 4d ago

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.